EDE Dengue monoclonal antibodies

Applications: Post-exposure therapy, Pre-exposure prophylaxis, Outbreak ring prophylaxis, High-risk healthcare exposure, Serotype-agnostic treatment, Reference assay standards, Emergency stockpiles

Clinical ready human monoclonal antibodies that target the Envelope Dimer Epitope on dengue virions, enabling cross-serotype neutralisation from a single conserved site and deployable IgG/fragment formats for passive immunisation.

Features	Benefits
Demonstrated broad neutralisation of dengue virions produced in insect and human cells	Single-antibody approach supports cross-serotype coverage
Two antibody classes (EDE1/EDE2) with distinct breadth profiles characterised in vitro	Streamlines development by focusing on a conserved dimer epitope
Reported therapeutic activity of EDE antibodies against Zika in preclinical studies	Suitable for prophylactic or therapeutic passive immunization use cases
Compatible with multiple molecular formats (full IgG and fragments)	Enables consistent antigen/assay alignment around the E-dimer epitope
Epitope definition and assays anchored to native virion quaternary structure	Supported by breadth across diverse clinical strains in cell-based assays
Binds a quaternary epitope spanning the E-protein dimer interface across DENV-1–4	Potential spill over utility against related flaviviruses (e.g., Zika)
Clinical-ready asset with first-in-human trial planned

Patent number: WO2016012800A1

Publications:

https://www.nature.com/articles/ni.3849

https://www.nature.com/articles/ni.3058

Request more information
about this technology

Back to Technologies Available

Technologies for License

EDE Dengue monoclonal antibodies

Ready to get in touch?